IP Library Granted Patent US 11,155,824
Granted Patent B2
US 11,155,824 · App. 15/762,551 · Granted Oct 26, 2021

Episomal plasmid vectors

Inventors: Thomas Vogl (Graz, AT); Anton Glieder (Gleisdorf, AT); Richard Wasmayer (Leoben, AT)
Assignee: BISY E.U.
C12N15/815C12N15/81C40B50/06C12N2800/108
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,155,824
App. No.
15/762,551
Granted
Oct 26, 2021
Kind
B2
Abstract

An episomal plasmid comprising a gene of interest (GOI) and an autonomously replicating sequence (ARS) which is not operably linked to the GOI, which ARS comprises or consists of a nucleotide sequence identified as any of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:6-11, or a functionally active variant of any of the foregoing which is characterized by at least 60% sequence identity thereto.

Claims (15)

1. A host cell of the genus Pichia having an episomal plasmid, wherein the episomal plasmid comprises an autonomously replicating sequence (ARS) and an expression cassette comprising a recombinant gene of interest (GOI), and wherein the ARS is positioned on said plasmid outside of said expression cassette and comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:5-11.

2. The host cell of claim 1 , wherein the episomal plasmid further comprises a selection marker and wherein the selection marker provides the host cell with a trait selected from the group consisting of auxotrophy and chemical resistance.

3. The host cell of claim 2 , wherein the trait is selected from the group consisting of glycerol utilization, sucrose utilization, inulin utilization, cellobiose utilization, amino acid auxotrophy, thymidine auxotrophy, nitrogen source utilization, resistance to fluoracetamide, resistance to deoxyglucose, resistance an antibiotics, and resistance to a gene encoding a toxin.

4. The host cell of claim 1 , wherein the episomal plasmid comprises a promoter which is operably linked to the GOI.

5. The host cell of claim 4 , wherein the promoter is a regulatable or constitutive promoter of Pichia pastoris selected from the group consisting of alcohol oxidase 1 promoter (AOX1), glyceraldehydes-3-phosphate dehydrogenase promoter (GAP), alcohol oxidase promoter (AOD), alcohol oxidase 2 promoter (AOX2), dihydroxyacetone synthase 1 promoter (DAS1), dihydroxyacetone synthase 2 promoter (DAS2), enolase 1 promoter (ENO1), formaldehyde dehydrogenase 1 promoter (FLD1), formate dehydrogenase promoter (FMD), glycerate phosphomutase 1 promoter (GPM1), heat shock protein 82 promoter (HSP82), isocitrate lyase 1 promoter (ICL1), acetohydroxyacid reductoisomerase promoter (ILV5), karyogamy 2 promoter (KAR2), kexin 2 promoter (KEX2), ADP, ATP carrier protein 2 promoter (PETS), peroxisomal biogenesis factor 8 promoter (PEX8), 3-phosphoglycerate kinase 1 promoter (PGK1), phosphate-responsive promoter/nuclear shuttle protein promoter (PHO89/NSP), stress-seventy subfamily A promoter (SSA4), translational elongation factor 1 promoter (TEF1), thiamine repressible promoter (THI11), triosephosphate isomerase 1 promoter (TPI1), GTP-binding protein promoter (YPT1), GTP binding protein 1 promoter (GTH1), GCW14 promoter (GCW14), and glycerol kinase promoter (GUT1).

6. The host cell of claim 4 , wherein the promoter comprises the nucleotide sequence of SEQ ID NO:4.

7. The host cell of claim 1 , wherein the episomal plasmid is produced in a host cell by a method comprising the steps of:

(i) providing a linear vector backbone comprising recombination sites at its 5′ and 3′ ends and the ARS;

(ii) providing a vector insert comprising a GOI and 5′ and 3′ homologous sequences which are homologous to the recombination sites; and

(iii) introducing the linear vector backbone and the vector insert into the host cell and recombining the vector insert with the recombination sites by homologous recombination, thereby producing the episomal plasmid comprising the GOI.

8. The host cell of claim 7 , wherein the linear vector backbone and the insert are introduced into the host cell at a molar ratio of between 1:1 and 1:10.

9. The host cell of claim 7 , wherein the vector backbone further comprises a selection marker and wherein the selection marker provides the host cell with a trait selected from the group consisting of auxotrophy and chemical resistance.

10. The host cell of claim 9 , wherein the trait is selected from the group consisting of glycerol utilization, sucrose utilization, inulin utilization, cellobiose utilization, amino acid auxotrophy, thymidine auxotrophy, nitrogen source utilization, resistance to fluoracetamide, resistance to deoxyglucose, resistance to an antibiotic, and resistance to a gene encoding a toxin.

11. The host cell of claim 1 , wherein the host cell is a strain of Pichia pastoris.

12. A method of producing a protein of interest (POI) that is encoded by the GOI of the episomal plasmid of claim 1 , comprising the step of cultivating the host cell of claim 1 under conditions to express said GOI, thereby producing the POI.

Assignments (3)
CHANGE OF NAME Recorded Dec 19, 2019
From: BISY E.U.
To: BISY GMBH
Reel/Frame 051339/0174 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2018
From: VOGL, THOMAS; GLIEDER, ANTON; WASMAYER, RICHARD
To: TECHNISCHE UNIVERSITÄT GRAZ
Reel/Frame 045329/0017 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2018
From: TECHNISCHE UNIVERSITÄT GRAZ
To: BISY E.U.
Reel/Frame 045329/0056 →
Priority Claims (1)
EP 15187431 · Sep 29, 2015 · regional
Continuity (1)
Related Publication 20190078104A1 · Mar 14, 2019